Skip to content

    Recently Viewed



      Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine

      The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

      Share Article
      share to

      Johnson & Johnson scientists are fast at work on a potential vaccine for COVID-19 that our company plans to provide on a not-for-profit basis.

      It’s a decision that underscores our company’s deep commitment to its 77-year-old mission statement, known as Our Credo, which states that Johnson & Johnson’s “first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality.”

      That commitment permeates the decisions that Gorsky makes both inside and outside our company, especially during this coronavirus pandemic.

      In this Financial Times profile, read about the decision to make the vaccine available on a not-for-profit basis, his work to help redefine the purpose of corporations through the U.S. Business Roundtable—and his people-first approach to leading at Johnson & Johnson.

      Read the article: Johnson & Johnson Chief Looks to the Greater Good

      How Johnson & Johnson Is Responding to the COVID-19 Pandemic

      Learn about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.

      More from Johnson & Johnson

      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.